Updates and Events

NEW YORK, N.Y. — June 2. Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.  Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through the […] READ MORE

June 1, 2023 What a month May was!  As we reflect upon Lupus Awareness month, the community continues to inspire.  We celebrate how ManyOne Can make a difference, and we salute all the accomplishments of those that ARE making a difference every day. Thank you for your dedication and support! Together, the community has: Advanced […] READ MORE

May 31, 2023 We are pleased to share encouraging news from EULAR, the annual meeting of the European Alliance of Associations for Rheumatology of Phase 2 data presented showing that upadacitinib improved SLE disease activity and time to first flare while lowering the need for steroids. Side effects were consistent with the known safety profile.  Discovered and […] READ MORE

The Lupus Landmark Study, the largest prospective observational study in lupus, will enroll 3,500 patients throughout North America over five years The Lupus Landmark Study is a key component of the Lupus Nexus, a first-of–its-kind in lupus registry, biorepository and data/knowledge portal  NEW YORK, NY (May 23) – The Lupus Research Alliance and its clinical […] READ MORE

The Lupus Research Alliance is pleased to report that the Lupus Accelerating Breakthroughs Consortium (Lupus ABC) held its inaugural meeting on April 16-17 in Bethesda, Maryland.  Lupus ABC is the first public-private partnership with the U.S. Food and Drug Administration (FDA) to focus specifically on advancing the development of safer and more effective treatments urgently […] READ MORE

EAST RUTHERFORD, NEW JERSEY. May 6, 2023. An enthusiastic crowd of nearly 1,500 supporters came together today at MetLife Stadium for the Lupus Research Alliance (LRA) 2023 New Jersey Walk with Us to Cure Lupus to raise nearly $500,000 for lupus research as well as public awareness of the serious and commonly misdiagnosed autoimmune disease. […] READ MORE

May 1, 2023 The LRA and our clinical arm Lupus Therapeutics are pleased to share good news from Cabaletta Bio, Inc. that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CABA-201, a CAR T cell investigational therapy in development to treat systemic lupus erythematosus and lupus nephritis – a common […] READ MORE

May 1, 2023 Last year, the Lupus Research Alliance launched our ManyOne Can campaign during Lupus Awareness Month to offer opportunities to get involved in our efforts to transform lives of people with lupus. This Lupus Awareness Month, we celebrate the great successes that are already being achieved and exciting ventures coming up that involve […] READ MORE

April, 2023 Tips to Lower Stress During Stress Awareness Month and Beyond If you are a person with lupus and often feel stress, you’re not alone! Research has shown stress is common among people dealing with a chronic condition like lupus and can cause symptoms like depression, fatigue, and disease flares. In recognition of Stress […] READ MORE

Winning projects will explore new potential treatment approaches to prevent lupus from developing or prevent or slow disease progression. New York, NY, April 20. The Lupus Research Alliance (LRA) today announced the newest Lupus Mechanisms and Targets Award grant recipients. The winning four projects collectively test potential treatment approaches to prevent lupus from developing or […] READ MORE

Lupus Accelerating Breakthroughs Consortium to address challenges impacting lupus trial success and to accelerate treatment breakthroughs  Washington, DC, March 29, 2023 – The Lupus Research Alliance (LRA) today announced the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), a first-of-its-kind public-private partnership bringing people with lupus together in collaboration with the U.S. Food and Drug Administration (FDA), […] READ MORE

March 27, 2023 Based on positive results of a Phase 2 clinical trial testing upadacitinib (Rinvoq®) given alone or with elsubrutinib once daily for moderate to severe systemic lupus erythematosus, developer AbbVie is advancing the drug to a Phase 3 trial. The trial also showed that steroid dose either went down or stayed the same […] READ MORE